Profile
| Role | 10% Owner |
|---|---|
| Notability | 30/100 |
Updated Jul 16, 2026
Lynx1 Capital Management LP has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $48.84M. Historical track record: 4/5 stars across 27 tracked purchases.
| Role | 10% Owner |
|---|---|
| Notability | 30/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★☆ (4/5) |
|---|---|
| Total purchases tracked | 27 |
| Purchases with forward-return data | 27 |
| 30-day win rate | 6667% |
| 90-day win rate | 6667% |
| Avg 5-day return | +1278.39% |
| Avg 30-day return | +881.35% |
| Avg 90-day return | +1378.59% |
| Best 30-day return | +3392.23% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-29 | PASG | Passage BIO, Inc. | P — Open-market purchase | 50.1K | $4.12 | $206K |
| 2026-04-02 | KRRO | Korro Bio, Inc. | P — Open-market purchase | 520 | $10.60 | $6K |
| 2025-12-23 | TCRX | TScan Therapeutics, Inc. | P — Open-market purchase | 6.2K | $0.90 | $6K |
| 2025-12-23 | TCRX | TScan Therapeutics, Inc. | P — Open-market purchase | 75.5K | $0.90 | $68K |
| 2025-12-23 | TCRX | TScan Therapeutics, Inc. | P — Open-market purchase | 80.1K | $0.90 | $72K |
| 2025-10-30 | CGEM | Cullinan Therapeutics, Inc. | P — Open-market purchase | 165.7K | $8.40 | $1.39M |
| 2025-10-23 | NEUP | Neuphoria Therapeutics Inc. | P — Open-market purchase | 639.1K | $5.14 | $3.28M |
| 2025-10-21 | CGEM | Cullinan Therapeutics, Inc. | P — Open-market purchase | 32.2K | $7.84 | $253K |
| 2025-10-21 | CGEM | Cullinan Therapeutics, Inc. | P — Open-market purchase | 150.0K | $8.86 | $1.33M |
| 2025-10-21 | CGEM | Cullinan Therapeutics, Inc. | P — Open-market purchase | 51.5K | $7.94 | $409K |
| 2025-10-21 | CGEM | Cullinan Therapeutics, Inc. | P — Open-market purchase | 15.0K | $7.59 | $114K |
| 2025-10-08 | CGEM | Cullinan Therapeutics, Inc. | P — Open-market purchase | 277.3K | $7.36 | $2.04M |
| 2025-10-08 | CGEM | Cullinan Therapeutics, Inc. | P — Open-market purchase | 626.0K | $6.70 | $4.19M |
| 2025-10-08 | CGEM | Cullinan Therapeutics, Inc. | P — Open-market purchase | 556.3K | $6.46 | $3.59M |
| 2025-09-11 | PASG | Passage BIO, Inc. | P — Open-market purchase | 11.9K | $6.99 | $83K |
| 2025-09-11 | PASG | Passage BIO, Inc. | P — Open-market purchase | 19.8K | $6.99 | $138K |
| 2025-09-11 | PASG | Passage BIO, Inc. | P — Open-market purchase | 325 | $6.96 | $2K |
| 2025-07-22 | PASG | Passage BIO, Inc. | P — Open-market purchase | 66.4K | $5.71 | $379K |
| 2025-07-22 | PASG | Passage BIO, Inc. | P — Open-market purchase | 49.3K | $5.74 | $283K |
| 2025-07-22 | PASG | Passage BIO, Inc. | P — Open-market purchase | 13.1K | $5.44 | $71K |
Lynx1 Capital Management LP is a corporate insider — currently tracked as 10% Owner of Passage BIO, Inc. (PASG). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 28 open-market purchases ($48.84M) and 0 open-market sales () across all tracked filings.
Across 27 tracked purchases, Lynx1 Capital Management LP averaged +881.4% avg 30-day return with a 6667% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lynx1 Capital Management LP profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.